Thursday, August 23, 2012
Sunday, August 12, 2012
New article from Current Biology promoting use of psilocybin for depression
Neuroimaging: a scanner, colourfully.
Two recent studies report changes in human brain responses after exposure to psilocybin, the active ingredient of hallucinogenic mushrooms. Psilocybin increased sensory cortex responses during emotional recollection, but decreased resting-state blood flow in prefrontal cortex, with potential implications for treating depression. Roiser JP, Rees G. Curr Biol. 2012 Apr 10;22(7):R231-3. PMID: 22497939
Cited by (Google Scholar)
And here is a recent article that describes the use of Ayahuasca for depression:
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study.
Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of ayahuasca in a bigger sample and to investigate its effects on regional cerebral blood flow. In an open-label trial conducted in an inpatient psychiatric unit, 17 patients with recurrent depression received an oral dose of ayahuasca (2.2 mL/kg) and were evaluated with the Hamilton Rating Scale for Depression, the Montgomery-Åsberg Depression Rating Scale, the Brief Psychiatric Rating Scale, the Young Mania Rating Scale, and the Clinician Administered Dissociative States Scale during acute ayahuasca effects and 1, 7, 14, and 21 days after drug intake. Blood perfusion was assessed eight hours after drug administration by means of single photon emission tomography. Ayahuasca administration was associated with increased psychoactivity (Clinician Administered Dissociative States Scale) and significant score decreases in depression-related scales (Hamilton Rating Scale for Depression, Montgomery-Åsberg Depression Rating Scale, Brief Psychiatric Rating Scale) from 80 minutes to day 21. Increased blood perfusion in the left nucleus accumbens, right insula and left subgenual area, brain regions implicated in the regulation of mood and emotions, were observed after ayahuasca intake. Ayahuasca was well tolerated. Vomiting was the only adverse effect recorded, being reported by 47% of the volunteers. Our results suggest that ayahuasca may have fast-acting and sustained antidepressive properties. These results should be replicated in randomized, double-blind, placebo-controlled trials.
Sanches RF, de Lima Osório F, Dos Santos RG, Macedo LR, Maia-de-Oliveira JP, Wichert-Ana L, de Araujo DB, Riba J, S Crippa JA, Hallak JE.
J Clin Psychopharmacol. 2015 Dec 8. [Epub ahead of print]
PMID: 26650973
Cited by (Google Scholar)
Two recent studies report changes in human brain responses after exposure to psilocybin, the active ingredient of hallucinogenic mushrooms. Psilocybin increased sensory cortex responses during emotional recollection, but decreased resting-state blood flow in prefrontal cortex, with potential implications for treating depression. Roiser JP, Rees G. Curr Biol. 2012 Apr 10;22(7):R231-3. PMID: 22497939
Cited by (Google Scholar)
And here is a recent article that describes the use of Ayahuasca for depression:
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study.
Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of ayahuasca in a bigger sample and to investigate its effects on regional cerebral blood flow. In an open-label trial conducted in an inpatient psychiatric unit, 17 patients with recurrent depression received an oral dose of ayahuasca (2.2 mL/kg) and were evaluated with the Hamilton Rating Scale for Depression, the Montgomery-Åsberg Depression Rating Scale, the Brief Psychiatric Rating Scale, the Young Mania Rating Scale, and the Clinician Administered Dissociative States Scale during acute ayahuasca effects and 1, 7, 14, and 21 days after drug intake. Blood perfusion was assessed eight hours after drug administration by means of single photon emission tomography. Ayahuasca administration was associated with increased psychoactivity (Clinician Administered Dissociative States Scale) and significant score decreases in depression-related scales (Hamilton Rating Scale for Depression, Montgomery-Åsberg Depression Rating Scale, Brief Psychiatric Rating Scale) from 80 minutes to day 21. Increased blood perfusion in the left nucleus accumbens, right insula and left subgenual area, brain regions implicated in the regulation of mood and emotions, were observed after ayahuasca intake. Ayahuasca was well tolerated. Vomiting was the only adverse effect recorded, being reported by 47% of the volunteers. Our results suggest that ayahuasca may have fast-acting and sustained antidepressive properties. These results should be replicated in randomized, double-blind, placebo-controlled trials.
Sanches RF, de Lima Osório F, Dos Santos RG, Macedo LR, Maia-de-Oliveira JP, Wichert-Ana L, de Araujo DB, Riba J, S Crippa JA, Hallak JE.
J Clin Psychopharmacol. 2015 Dec 8. [Epub ahead of print]
PMID: 26650973
Cited by (Google Scholar)
Wednesday, August 8, 2012
PTSD, Mindfulness and Yoga: Huffington 08/07/2012
Yoga: How We Serve Our Veterans
This is an interview with Felice Brenner, who had been working as a "headhunter" for 20 years to become a full-time yoga instructor. She teaches two classes a week at the Veterans Administration in Boston, Jamaica Plains campus. This year, Felice received the Outstanding Federal Volunteer award from the VA Boston Healthcare System for her service and commitment. Huffington Post
This is an interview with Felice Brenner, who had been working as a "headhunter" for 20 years to become a full-time yoga instructor. She teaches two classes a week at the Veterans Administration in Boston, Jamaica Plains campus. This year, Felice received the Outstanding Federal Volunteer award from the VA Boston Healthcare System for her service and commitment. Huffington Post
Monday, August 6, 2012
New Study on PTSD in the Journal Mindfulness
A Prospective Investigation of Mindfulness Skills and Changes in Emotion Regulation Among Military Veterans in Posttraumatic Stress Disorder Treatment
We prospectively investigated associations between mindfulness and changes in the use of expressive suppression and cognitive reappraisal occurring during a residential treatment program for posttraumatic stress disorder (PTSD). The sample consisted of 50 male veterans who were assessed with the Kentucky Inventory of Mindfulness Skills at treatment intake, and the Emotion Regulation Questionnaire (ERQ) and PTSD Checklist—Military Version at treatment intake and discharge. Hierarchical multiple regressions indicated that greater nonjudgmental acceptance at intake predicted greater reductions in expressive suppression (p < .05) and less improvement in cognitive reappraisal (p < .05) between treatment intake and discharge. Additionally, greater ability to observe thoughts, emotions, and sensations at intake was associated with less improvement in cognitive reappraisal between treatment intake and discharge (p < .05). Findings remained significant after statistically adjusting for treatment-related changes in PTSD symptoms.
2012, DOI: 10.1007/s12671-012-0131-4
Thursday, August 2, 2012
Lancet: a new editorial on psychedelic research
Shaping the renaissance of psychedelic research
Psychedelic drugs have a rich and vibrant history as clinical aids for psychiatry. For two decades after the discovery of lysergide (LSD) in the 1940s, psychedelics were extensively studied and clinical progress was good. But research collapsed rapidly in 1966 when LSD was made illegal, and there was a subsequent hiatus of psychedelic research. After 40 years, this pause is now coming to an end, with many new studies and a refreshing approach to the research of psychedelic drugs. Lancet. 2012 Jul 21;380(9838):200-1. No abstract available. PMID: 22817963
Psychedelic drugs have a rich and vibrant history as clinical aids for psychiatry. For two decades after the discovery of lysergide (LSD) in the 1940s, psychedelics were extensively studied and clinical progress was good. But research collapsed rapidly in 1966 when LSD was made illegal, and there was a subsequent hiatus of psychedelic research. After 40 years, this pause is now coming to an end, with many new studies and a refreshing approach to the research of psychedelic drugs. Lancet. 2012 Jul 21;380(9838):200-1. No abstract available. PMID: 22817963
Subscribe to:
Posts (Atom)